TrialThe Journal of antimicrobial chemotherapy2024

First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug.

Michel Pieren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.